Skip to main content

Resource Download
FDA’s New Breakthrough Therapy Designation: What does it mean for Pricing

The full impact of the breakthrough therapy designation remains to be seen,but the financial stakes are high. Therefore, it is important to assess how P&MA planning practices need to be adapted to take advantage of a potential breakthrough designation. Re-evaluation of P&MA activities is prudent for any manufacturer hoping to secure big wins in the face of future break-through drug launches.


Download your copy

EPP Pricing Platform will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy page.